Australia Self-Monitoring Blood Glucose Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia self-monitoring blood glucose market is maturing rather than disappearing. Fingerstick testing once defined diabetes self-care, but sensors now serve most people with type 1 diabetes, so growth depends on type 2 diabetes, pregnancy-related diabetes and people who are not eligible for subsidised sensors.

Three forces shape demand: the National Diabetes Services Scheme, which subsidises strips and offers free meters; continuing sensor substitution, shown by the delisting of Dexcom G6 from 1 October 2026 and FreeStyle Libre 2 from 1 July 2026; and supplier rationalisation, as older strip brands leave the scheme.

In July 2026 Pharmx Technologies renewed its NDSS ordering agreement to July 2028, in May 2026 the government only noted a call to widen sensor access, and in February 2026 diabetes groups sought AUD 106.48 million for sensors.

Key Market Trends and Insights

• Large registered base: The Australian Institute of Health and Welfare reports about 1.5 million NDSS registrants in 2025, and the Australian Diabetes Society counted 1,326,834 with type 2 diabetes in December 2025, a steady base for strips.
• Sensor substitution: Breakthrough T1D said in February 2026 that more than 70% of Australians with type 1 diabetes use continuous monitoring, which caps strip use in the group most exposed to sensors.
• Funding decision deferred: The government marked a call to widen sensor access as noted on 26 May 2026 and cited AUD 682.3 million already committed, leaving most people with type 2 diabetes on fingerstick testing.
• Brand rationalisation: NDSS removed TRUE Metrix and Lifesmart 2 Twoplus strips on 31 January 2025 and Rightest GS700 strips on 1 August 2025, forcing meter changes and favouring suppliers with broad local support.

Australia Self-Monitoring Blood Glucose Market Size and Forecast

The market is moving from a broad volume business towards a smaller, more targeted fingerstick base focused on people who are not served by subsidised sensors. Test strips lead because every check consumes one, while meters advance fastest as supplier exits and connected models renew the installed base. Gestational diabetes grows quickest among diabetes types, and online supply gains share as suppliers deliver free meters directly to registrants. New South Wales stays the largest state while Western Australia grows fastest. Subsidy rules, sensor policy decisions and pharmacy ordering systems point to a stable but slow-growing outlook.

Key Takeaways: Australia Self-Monitoring Blood Glucose Market

Subsidised Pharmacy Access Keeps Fingerstick Testing Routine

Revenue is on course to expand by about 21% across the decade, from AUD 310.00 million in 2025 to AUD 374.20 million in 2035 at a 1.9% CAGR. Pharmacy supply, free meters and a type 2 diabetes base of 1,326,834 NDSS registrants make demand recurring, though sensor substitution keeps growth modest.

Meters, Gestational Diabetes and Online Supply Lead Growth

Test Strips hold the largest revenue share, but Blood Glucose Meters grow at an estimated 2.9% CAGR, Gestational Diabetes at 3.4% and Online Pharmacies and Mail Order at 4.1% through 2035. Supplier exits and direct delivery of free meters explain the upside.

Sensor Funding Decision Remains Open

On 26 May 2026 the government noted a parliamentary recommendation to extend subsidised sensors to more people, pointing to existing funding rather than committing to expansion. Any widening would shift volume away from strips, so the decision is the main swing factor.

• AUD 682.3 million committed over four years from 2022-23
• Only nine of 23 inquiry action items supported in principle
• AUD 106.48 million sought for about 16,000 people in February 2026

Australia Self-Monitoring Blood Glucose Market Report Summary

Key Insight

Subsidised pharmacy access keeps fingerstick testing routine for most registrants, while sensor substitution caps growth. Meters, pregnancy-related diabetes and online supply advance fastest across the forecast period.

Key Trends in the Australia Self-Monitoring Blood Glucose Market

The Australia self-monitoring blood glucose market is being shaped by sensor delistings, unresolved funding decisions and advocacy for wider subsidised access.

July 2026 - NDSS Delists Dexcom G6 Transmitters and Sensors From October

• The scheme announced on 10 July 2026 that Dexcom G6 transmitters and sensors leave the NDSS from 1 October 2026 after AMSL Diabetes discontinued them.
• The switch is not automatic, so users must book a health professional to move to another monitor.
• Product exits leave meters and strips as the common backup during any gap between sensor devices.

June 2026 - FreeStyle Libre 2 Sensor Leaves NDSS as Libre 2 Plus Takes Over

• The NDSS announced on 1 June 2026 that Abbott Diabetes Care discontinued the FreeStyle Libre 2 sensor, delisted from 1 July 2026.
• Users move automatically to Libre 2 Plus by 30 June 2026, with a co-payment of AUD 17.90 per sensor.
• Concession card holders and registrants under 21 pay no co-payment, which keeps sensors affordable for those groups.

May 2026 - Government Notes Call to Widen Subsidised Sensor Access

• On 26 May 2026 the government marked a parliamentary recommendation on wider sensor access as noted, not supported in principle.
• It pointed to AUD 682.3 million committed over four years from 2022-23 and said it would consider expansion in future.
• People with type 2 diabetes who use insulin therefore remain mainly on fingerstick testing.

February 2026 - Diabetes Groups Seek Budget Funding for Sensors and Insulin Delivery

• Diabetes Australia's release of 24 February 2026 sought AUD 106.48 million over four years for sensors for about 16,000 people.
• Priority groups include people on intensive insulin, Aboriginal and Torres Strait Islander people, people under 21 and women planning pregnancy.
• A separate AUD 298.95 million request targeted automated insulin delivery for about 38,000 people with type 1 diabetes.

Key Insight

Sensor product exits and unresolved funding decisions shape the policy backdrop, and each change keeps meters and strips in demand as the backup for people moving between monitoring devices.

Recent Market Developments in the Australia Self-Monitoring Blood Glucose Market

Recent developments, presented from the most recent, show the Australia self-monitoring blood glucose market moving from pharmacy ordering and supplier restructuring into earlier brand exits.

July 2026 - Pharmx Technologies Renews NDSS Ordering Agreement to 2028

• Pharmx Technologies renewed its agreement with the NDSS for 24 months, running through July 2028, as reported on 14 July 2026.
• NDSS ordering is a widely used digital workflow in Australian pharmacies, linking dispensing to subsidised supply.
• Stable ordering links help pharmacies handle strips, meters and sensors in one process.

March 2026 - Roche Withdraws Insulin Pump Consumables From NDSS

• The NDSS announced on 20 March 2026 that nine Roche products would lose subsidy from 30 June 2026 as Roche discontinued its pump consumables.
• The notice covers pump products only, and Accu-Chek Guide Me remains listed on Roche's Australian site.
• Roche now concentrates its local diabetes range on monitoring, supporting its Accu-Chek meter and strip line.

February 2026 - Ascensia Diabetes Care Names Peter Bodlund Chief Executive

• Ascensia announced on 24 February 2026 that Peter Bodlund would become president and chief executive from 1 April 2026.
• He was previously chief operating officer, and predecessor Koichiro Sato stays as chief operating officer of PHC Group.
• Contour is Ascensia's best-known product line, sold in more than 100 countries with direct operations in 29.

August 2025 - NDSS Removes Rightest GS700 Strips From the Product Schedule

• The NDSS announced on 11 June 2025 that Rightest GS700 strips would leave the schedule from 1 August 2025.
• Users had to switch to a new meter and matching strips, and could request a free meter.
• The exit followed the removal of TRUE Metrix and Lifesmart 2 Twoplus strips on 31 January 2025.

Key Insight

Pharmacy ordering stability, supplier restructuring and product delistings show a market consolidating around fewer strip brands while suppliers redirect resources. Momentum favours established, locally supported meter ranges.

Australia Self-Monitoring Blood Glucose Industry Segmentation

The Expert Market Research’s report on the Australia Self-Monitoring Blood Glucose Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Test Strips
• Blood Glucose Meters
• Lancets and Lancing Devices
• Control Solutions and Accessories
• Others

Test Strips lead because every fingerstick check consumes one, and NDSS removed TRUE Metrix and Lifesmart 2 Twoplus strips in January 2025 and Rightest GS700 strips in August 2025, moving users to other brands. Blood Glucose Meters grow fastest at an estimated 2.9% CAGR through 2035, as those forced switches and connected models such as Contour Next One and Accu-Chek Guide Me renew the installed base. Lancets and Lancing Devices follow testing frequency, and Ascensia moved Microlet lancets to colour options in 2025. Control Solutions and Accessories support accuracy checks. Others include ketone strips for dual meters such as GlucoKey and FreeStyle Optium Neo.

Market Breakup by Diabetes Type

• Type 2 Diabetes
• Type 1 Diabetes
• Gestational Diabetes
• Others

Type 2 Diabetes leads, with 1,326,834 NDSS registrants in December 2025 against 144,022 with type 1, and grows at an estimated 2.0% CAGR through 2035 as most users stay on strips. Gestational Diabetes is fastest at an estimated 3.4%, because the government in May 2026 only noted a recommendation to extend subsidised sensors to gestational diabetes, which leaves fingerstick testing the standard in pregnancy. Type 1 Diabetes grows slowest at an estimated 0.6%, since Breakthrough T1D said in February 2026 that over 70% of Australians with type 1 already use sensors. Others cover type 3c diabetes and rarer forms, growing at an estimated 2.2%.

Market Breakup by Distribution Channel

• Community Pharmacies
• Online Pharmacies and Mail Order
• Hospitals and Clinics
• Others

Community Pharmacies lead because NDSS products are supplied through participating pharmacies, over 97% of eligible pharmacies took part in 2022, and Pharmx renewed its NDSS ordering agreement to July 2028 in July 2026. Online Pharmacies and Mail Order grows fastest at an estimated 4.1% CAGR through 2035, as Ascensia delivers a free Contour Next meter to each NDSS registrant every 18 months and Pharmaco ships its meters through its website. Hospitals and Clinics start new patients on meters, with Abbott directing registrants to diabetes clinics and professionals ordering CareSens N Voice from Pharmaco. Others include aged care and community health supply.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates with 8.67 million residents in March 2026, and grows at an estimated 1.6% CAGR through 2035. Western Australia is fastest at an estimated 2.5%, after population growth of 2.1% in the year to March 2026, the quickest of any state. Queensland, at an estimated 2.2%, added 90,100 residents to reach 5.74 million, while Victoria, at 1.9%, grew 1.6% to 7.15 million. South Australia, with 1.92 million residents, grows slowest at 1.4%. Others covers Tasmania, the ACT and the Northern Territory, growing at an estimated 1.7%, with 268,900 residents in the Northern Territory.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Self-Monitoring Blood Glucose Market

Competition combines global meter makers and local distributors. Barriers include listing on the NDSS schedule, free meter programs that tie users to proprietary strips, pharmacy ordering integration, Therapeutic Goods Administration registration and clinician familiarity.

Roche

Roche, headquartered in Basel, Switzerland, was founded in 1896 and sells the Accu-Chek range in Australia through Roche Diabetes Care, including the Guide and Guide Me meters, which its local site presents as the successor to the retired Performa and which connect to the mySugr app. In March 2026 the NDSS announced that Roche would discontinue insulin pump consumables from 30 June 2026. Roche reported group sales of CHF 30.36 billion for the first half of 2026.

Ascensia Diabetes Care

Ascensia Diabetes Care, headquartered in Basel, Switzerland, was formed in 2016 when PHC Holdings acquired Bayer Diabetes Care, and its Australian arm in Bella Vista, New South Wales, launched Contour Next and Contour Next One in 2018. It sells Microlet lancets, which moved to colour options in 2025, and offers one free Contour Next meter per NDSS registrant every 18 months. Peter Bodlund became chief executive in April 2026, and Eversense operations began moving to Senseonics in January 2026.

Abbott

Abbott, headquartered in Abbott Park, Illinois, was founded in 1888 and appears on the NDSS free meter list with FreeStyle Optium Neo and other FreeStyle meters, alongside FreeStyle Libre sensors. The NDSS began subsidising Libre 2 Plus on 1 April 2025 and announced in June 2026 that Libre 2 leaves the scheme on 1 July 2026. Abbott reported second-quarter 2026 Diabetes Care sales of USD 2,188 million, up 9.0% on a comparable basis.

Pharmaco (Australia)

Pharmaco (Australia), based in Chatswood, New South Wales, distributes the CareSens range made by i-SENS of Seoul, a company established in 2000. Its CareSens N, N Voice and Dual meters appear on the NDSS free meter list, and its site also lists ketone meters, SmartLog software and the CareSens Air sensor. i-SENS launched the CareSens Air Receiver in November 2025, and CareSens won the grand prize in its monitoring category at the First Brand Awards in January 2026.

Other players operating in the Australia self-monitoring blood glucose market include Nipro Australia, i-SENS, Owen Mumford, Bionime, and AMSL Diabetes, alongside pharmacy chains, online pharmacies, lancet suppliers and clinic distributors serving registrants across Australia.

Key Insight

Competition rests on subsidy listing, free meter offers, pharmacy availability and connected software rather than price alone, so suppliers with broad support and established networks hold the advantage.